H
UMA IIERPESVIRUS 6 (1111\16) WAS FIRST REPORTED IN 1986 by Salahuddin et al (l) following the isolalion of an agent from the peripheral blood mononuclear ce lls of a human immunodeficiency virus (HI V)-1 -infected AIDS patient. The virus was initially termed human B lymphotropic virus. but the name was changed after it was shown to have a diverse cellular tropism with a predominant affinity for CD4-positive T lymphocytes (2) . 1-11 rv6 is genetically most similar to human cytomegalovirus and possesses similar in vitro sensitivity to gancyclovir with some evidence of susceptibility to foscarnet (3) .
Serological cross-reactivity of IIIIV6 wiU1 other human h e rpesviruses does not seem to be significant and is seldom a factor in primary HHV6 infections in young children (4). However. reactivation or co-infection of other herpesviruses with I-IHV6 in transplantation patients or others with immunological alterations may complicate serological interpretation in these cases.
There are two recognized HI-IV6 strain groups typified by prototype GS or U 11 02-li ke isolates designated as 'Ill IV6 variant A and prototype Z29-like iso lates as 'III IV6 variant B' (5). Viruses be longing to each can be identified on the basis of differential reactivity with monoclonal antibodies. in vitro cell tropism and genetically by polymerase chain reaction and res triction enzyme cleavage patterns (6.7) . II IIV6 is a lso distingu ished from the recently described human herpesvirus 7 (HIIV7) by a va1iety of serological and mo lecu lar techniques (8) .
Infection with HHV6 is vi rtually universal in humans with serosurveys using sensitive methodologies in Canada (4) and other countries (9) ind icating that antibody prevalence is close to 100% in individuals four years old to middle age. A small decline in prevalence and a more marked decrease in mean level of antibody may be seen with increasing age after 40 years. Virtually all newborns h ave antibody to HHV6 because of placenta l transfer of antibody. with antibody litre and prevalence declining towards six monU1s of age. Although early JII IV6 p1irnary infections may occasionally occur in U1e presence of maternal antibody (10) . the rate of infection rises rap- idly up to one year of age. continues at a reduced rate into U1e second year and beyond wiU1 mean antibody levels pealting in this one-to four-year-old age group (4).
Previous research has ind icated that IIHV6 is the major. if not. the only, cau se of exanthema s u bitum or roseola infantu m in infants and young children (11) . The disease in young children typically has an abrupt. onset with fever lasting for a few clays and the appearance of a maculopapular rash coinciding wiU1 the decline in feve r. Suboccip ital lymph adenopathy is common . with one or more other symptoms such as diarrhea. vom iting. runny nose. cough and hepatomegaly less frequent.ly observed. Hematologically. neutropenia is prominent with relative lymphocytosis during the exanU1ema phase. The most common complication is convu ls ive seizu res. but even in these cases the prognosis is excellent. 1111\16 isolates in exanthema subitum are mosUy of the variant B type (12) . HHV6 has also been identified as an important cause of acute nonspecific febrile illness in young ch il dren in whom the height of the fever and the presence of symptoms not usually associated with roseola, such as otitis and diarrhea, can result in varied, time consuming and expensive workup in the emergency department (10) . In older children and adults, HI-N6 has been investigated for either a causative role or as a cofactor in a variety of conditions (Table 1) including, but not limited to, heterophile-negative infectious mononucleosis-like illness (13) . manow suppression in bone marrow transplant recipients (14) and as a cofactor in the progression of AIDS (15) . Hence, there is an obvious need for accurate. rapid laboratory diagnosis of HHV6 plimary infection and infection/reactivation in adult or immunosuppressed patients.
The Surveillance, Influenza and Viral Exanthemata section of the Laboratory Centre for Disease Control (LCDC) provides investigational HI-N6 diagnostic capabilities for a variety of specimen types. Sera provided with reasonable clinical documentation suggestive of HI-N6 involvement, patient age and an indication of the time of sampling relative to disease onset may b e forwarded for testing to LCDC via the provincial laboratories. In addition. specimens from specific collaborative studies may be accepted directly based on predetermined research objectives and agreements. Our cunent diagnostic methodologies for HHV6 include an enzyme-linked immunosorbent assay (ELISA) for serological identification of HI-N6-specific immunoglobulin (Ig) G. or IgM antibodies after IgG removal (4) as well as the potential for viral isolation and molecular characterization of isolates through polymerase chain reaction-based assays. The ELISA is based on HI-N6 antigen prepared from a continuous lymphocyte culture (HSB-2) infected with HHV6 variant A (GS) originally provided through a research agreement with the United States National Institutes of Health. HHV6 isolation can be attempted from appropriate specimens in either continuous HSB-2 lymphocytes or in primary cord blood lymphocytes.
During 1993 the LCDC analyzed sera from approximately 400 patients from across Canada and found that 54 (14%) demonstrated an IgG seroconversion and/or IgM. In addition , we analyzed serially collected sera from 22 transplantation patients and found that 36% of these patients had significant increases in either their IgG and/or IgM titres. Our studies h ave indicated that HHV6-specific IgM may not be present in primary HI-N6 infection until as late as four to seven days postonset of symptoms. This results in a low negative predictive value on HI-N6 IgM-negative serum specimens collected within a day or two of disease onset. However, early acute and convalescent sera taken seven to 10 days apart may show seroconversions in both IgM and IgG antibody.
We continue to investigate t.he epidemiological s ignificance and range of disease caused by HI-N6 through collaborative clinical studies at a number of centres, and are continuing in the development and evaluation of additional diagnostic assays such as Western blot analysis. The combination of viral isolation and molecu lar characterization should provide definitive identification of infecting strains and could prove useful in distinguishing the nature of individual strains in different disease states . However, both require further study and refinement before the results obtained with either can be generally and reliably interpreted in the conte::>..'t of acute and/or chronic infection diagnosis.
There has been substantial progress in understanding the role of HI-N6 infections in specific human diseases. Much remains to be detennined. however. and the combination of careful clinical studies and innovative diagnostic techniques will be required to continue to evaluate the pathological significance and impact of this virus.
